Diagnosing COVID-19 with the new isothermal amplification technology

NewsGuard 100/100 Score

Announcing a new article publication for Zoonoses journal. During the COVID-19 pandemic, polymerase chain reaction (PCR) has become the gold standard for the detection of SARS-CoV-2 RNA worldwide.

However, PCR-based nucleic acid detection technology remains relatively time consuming, and requires specialized instrumentation and technical personnel; therefore, PCR is difficult to apply at primary-level medical institutions.

Antibody-based detection has limitations because of the late appearance of antibodies, thus making early diagnosis difficult, whereas antigen-based detection has insufficient sensitivity, thus resulting in a high false-negative rate.

Here, the authors of this article briefly summarize the development and applications of the nucleic acid isothermal amplification technique (IAT) and describe four major IATs used for the detection of SARS-CoV-2 RNA in mainland China, which have been officially approved by the National Medical Products Administration, elaborating on the strengths and weakness of the different IAT in practical settings. The outlook for IAT development and propose considerations for the future use of IATs in China are also discussed.

Source:
Journal reference:

Ma, X., (2022) Isothermal Amplification Technology for Diagnosis of COVID-19: Current Status and Future Prospects. Zoonoses. doi.org/10.15212/ZOONOSES-2021-0022.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study reveals increased risk of allergic diseases after COVID-19 infection